drugset / Trial / NCT00633477

Efficacy and Safety of Resatorvid in Patients With Sepsis-induced Cardiovascular and Respiratory Failure

NCT00633477

Phase 3 Terminated 18 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the effect of resatorvid on subjects with sepsis.

Timeline

Start
2008-02
Primary completion
2009-02
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Resatorvid Small molecule 2.4 mg/kg